ArticleNature biotechnology2009

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

Marcin Kortylewski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.